The tempting board move is to rank NMOSD therapies by remembered relapse percentages. That can turn separate trials into a fictional head-to-head contest: the studies differed, and they do not establish one universally superior choice. The more useful question is: what patient factor, if any, makes one prevention strategy a better fit here?
Separate relapse prevention from attack treatment
If evaluation establishes AQP4-IgG-positive NMOSD, long-term attack prevention is a central treatment decision. NEMOS recommends offering preventive immunotherapy after the first attack; waiting for another relapse is not the default principle. Keep that decision separate from treatment of an active optic neuritis or myelitis attack: a prevention drug is not acute rescue therapy.
For adults in the United States, FDA-approved options include C5 inhibition with eculizumab or ravulizumab, CD19-directed B-cell depletion with inebilizumab, and IL-6 receptor inhibition with satralizumab. Rituximab is also used off label in NMOSD. The exam-level principle is to use NMOSD-appropriate relapse prevention, not to memorize a universal drug ranking.
Compare options by fit and safety
Mechanism is useful for remembering drug classes. It does not, by itself, tell you which treatment is best for an individual. Look for the detail the stem gives about safety, comorbidity, route, follow-up, or patient preference.
| Pathway and examples | What to check when the stem makes it relevant |
|---|---|
| C5 inhibition: eculizumab, ravulizumab | Check meningococcal vaccination and explain that infection risk remains despite vaccination. Follow current product-label guidance on timing and any measures needed if treatment cannot wait. |
| CD19-directed depletion: inebilizumab | Consider infection risk and the label-directed pretreatment checks, including hepatitis B and tuberculosis screening and quantitative immunoglobulins. Review vaccination timing. |
| IL-6 receptor inhibition: satralizumab | Check infection risk and label-directed pretreatment screening, including hepatitis B, tuberculosis, and liver transaminases. Monitor liver enzymes and neutrophils. Review vaccination timing; route and follow-up demands may matter if the vignette makes them relevant. |
These are high-yield safety prompts, not complete prescribing instructions or automatic exclusion rules. Apply the current product label and local protocol to an actual treatment decision.
Other useful selection factors include disease activity and severity, recovery from the previous attack, comorbidities, reproductive plans, administration preference, adherence, availability, and cost. If a vignette supplies none of these, do not invent a contraindication or preference to force one answer. State the appropriate prevention principle and avoid claiming that the evidence proves a single best agent.
Use the stem’s discriminator, not a guessed ranking
For a board-style multiple-choice item, first identify what is being tested: prevention of future NMOSD attacks, not treatment of the current attack. Next, recognize the disease-specific preventive options. Finally, use the clue the stem actually supplies to distinguish among otherwise reasonable choices.
If the stem highlights a preference for a self-administered subcutaneous option, route may support considering satralizumab—provided safety, access, and other clinical factors fit. That is a patient-fit rationale, not evidence that satralizumab prevents attacks better than the alternatives. If there is no distinguishing clue, do not manufacture one from a drug’s mechanism or a percentage recalled from a different trial.
A second common trap is reflexively substituting a multiple sclerosis disease-modifying therapy. Some MS therapies, including interferon beta, natalizumab, and fingolimod, are not appropriate choices for established NMOSD; severe attacks have been reported with some of them. When the diagnosis is established, answer for NMOSD rather than assuming treatments transfer between diagnoses.
An eight-minute revision exercise
This is a retrieval drill, not an exam timing rule. Close your notes. Give yourself three minutes to answer this compact prompt in three sentences: An adult has established AQP4-IgG-positive NMOSD after a first attack. The question asks about prevention, but gives no treatment preference or comorbidity. What principle can you defend—and what can’t you infer?
Your answer should capture three things: offer long-term prevention after the first attack; name appropriate NMOSD preventive options; and avoid claiming that one is superior without a meaningful discriminator. It should not invent patient history or drift into acute attack treatment.
Spend the next three minutes auditing your answer. Underline the evidence that supports the choice, then circle any claim of superiority. Ask whether that claim comes from a true head-to-head comparison or from comparing different trials. Check that you have not missed a drug-specific safety issue supplied by the stem.
For the final two minutes, add one explicit clue: the patient prefers a self-administered subcutaneous option. Rewrite only the selection sentence. A defensible revision can say that route makes satralizumab relevant to consider, while noting that safety checks and other individual factors still guide the decision. The point is to let new evidence change the reasoning—without turning a preference into an efficacy claim.
Practical takeaways
- Once AQP4-IgG-positive NMOSD is established, think about long-term prevention after the first attack; do not wait by default for a second.
- Separate prevention of future attacks from treatment of an active attack.
- Recall the targeted pathways, then select by the patient details provided—not by an unsupported cross-trial ranking.
- Check class-specific safety requirements, especially meningococcal risk with C5 inhibitors and screening or monitoring with other immunotherapies.
- Avoid reflexive use of MS disease-modifying therapies for established NMOSD.
